Anavex Life Sciences Corp.
AVXL
$4.32
-$0.25-5.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.98% | 17.65% | -1.78% | 0.69% | -8.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.34% | 9.19% | 11.19% | 7.74% | -4.62% |
| Operating Income | -0.34% | -9.19% | -11.19% | -7.74% | 4.62% |
| Income Before Tax | -7.85% | -15.82% | -16.06% | -7.80% | 9.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.85% | -15.99% | -16.13% | -7.73% | 9.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.85% | -15.99% | -16.13% | -7.73% | 9.48% |
| EBIT | -0.34% | -9.19% | -11.19% | -7.74% | 4.62% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -5.73% | -13.03% | -12.03% | -3.08% | 13.85% |
| Normalized Basic EPS | -5.75% | -12.88% | -11.99% | -5.41% | 12.11% |
| EPS Diluted | -5.73% | -13.03% | -12.03% | -3.08% | 13.85% |
| Normalized Diluted EPS | -5.75% | -12.88% | -11.99% | -5.41% | 12.11% |
| Average Basic Shares Outstanding | 2.18% | 2.72% | 3.61% | 4.14% | 4.62% |
| Average Diluted Shares Outstanding | 2.18% | 2.72% | 3.61% | 4.14% | 4.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |